000			02691nam a2200289Ia 4500
003			OSt
005			20251113121009.0
008			220909b |||||||| |||| 00| 0 eng d
020			_a9781482203875
037			_cTextbook
040			_aCSL _beng _cCSL
041			_aeng
084			_aC21:(D)0bL Q4 TE _qCSL
245		0	_c/ edited by Nancy A Monteoro-Riviere and C Lang Tran _aNanotoxicology _b: Progress toward nanomedicine
250			_a2nd
260			_aBoca Raton : _bCRC Press, _c2014.
300			_axix, 492p. _b: ill.
500			_aIndex 479-492p.
520			_aSince the first publication of this book in 2007, the field of nanoscience and nanomedicine continues to grow substantially. This second edition, Nanotoxicology: Progress toward Nanomedicine, enlists internationally recognized experts to document the continuing development and rationale for the safe design of engineered nanomaterials (ENM). This includes new improved characterization endpoints, screening, and detection methods for in vitro and in vivo toxicity testing. These tools also contribute greatly to nanosafety research applied to nanomedicines. Topics include The impacts of nanotechnology on biomedicine, including functionalization for tissue-specific targeting, the biointeractions of multifunctional nanoparticle-based therapy, and the ability to control specific physicochemical properties of nanoparticles The requirements for proper detection, measurement, and assessment both for workplace exposure and in consumer products—with a focus on potential health and safety implications Predictive modeling, using quantitative nanostructure activity relationships to predict the pharmacokinetics and biodistribution of nanomaterials in the body Specific methodologies, imaging, and techniques to assess nanomaterials from the manufacturing process to nanomedicine applications Tools for assessing nanoparticle toxicity and the limitations of detection methods for assessing toxicity in both in vivo and in vitro systems and at the single cell and tissue levels Toxicity of nanomaterials to specific organ systems, cell–based targeting to tumors, and other biomedical applications The difficulty of conducting risk assessments and the need for addressing knowledge gaps, especially with long-term studies A roadmap for future research
650			_a Cardiovasular disease _9851122
650			_a Nanoparticles and immune system _9851123
650			_a Risk assesment _9851124
650			_aBiomedical nanotechnology _9851125
700			_aMonteoro-Riviere, Nancy A _eeditor _9851126
700			_aTran, C Lang _eeditor _9851127
942			_hC21:(D)0bL Q4 TE _cTB _2CC _n0
999			_c6571 _d6571